Mini-Review

Certolizumab Pegol

Volume 2, Issue 2   March/April 2010
Pages 137 - 147
http://dx.doi.org/10.4161/mabs.2.2.11271
Authors: Niti Goel and Sue Stephens

View affiliations

Abstract:
Certolizumab pegol (Cimzia®) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab′) of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.

Received: December 14, 2009; Accepted: January 21, 2010

Preview:



Advertisements